The Generation of Antibodies against Human Coronavirus NL63 (HCoV-NL63) Nucleocapsid Protein
| dc.contributor.advisor | Fielding, B.C | |
| dc.contributor.author | Smith, Marjorie | |
| dc.date.accessioned | 2018-07-25T10:47:18Z | |
| dc.date.accessioned | 2024-11-04T13:15:29Z | |
| dc.date.available | 2018-08-31T22:10:06Z | |
| dc.date.available | 2024-11-04T13:15:29Z | |
| dc.date.issued | 2017 | |
| dc.description | Magister Scientiae - MSc (Medical BioSciences) | |
| dc.description.abstract | Coronaviruses (CoVs) are enveloped viruses composed of single-stranded, positive sense RNA viruses with the largest viral genomes among RNA viruses (27-33 kb). In 2004, human coronavirus NL63 (HCoV-NL63) was discovered by researchers from The Netherlands. Since its discovery, it has been found in countries all over the world and affects mainly young children between ages 0-5 years old, immunocompromised and elderly people. HCoV-NL63 has been indicated to cause both mild upper and more serious, but less common, lower respiratory tract infections and are commonly associated with other respiratory viruses in co-infections that can increase the severity of HCoV-NL63 infection. The nucleocapsid (N) protein of HCoV-NL63 is a multifunctional phosphoprotein that modulates the assembly of the ribonucleocapsid core of mature virions. During infection, the N protein is expressed at high levels within an infected cell and elicits a strong immune response in infected patients. For this reason, N protein was used to generate antibodies against an immune response to the presence of HCoV-NL63 N protein in mouse blood serum. | |
| dc.identifier.uri | https://hdl.handle.net/10566/17299 | |
| dc.language.iso | en | |
| dc.publisher | University of the Western Cape | |
| dc.rights.holder | University of the Western Cape | |
| dc.title | The Generation of Antibodies against Human Coronavirus NL63 (HCoV-NL63) Nucleocapsid Protein |
Files
Original bundle
1 - 1 of 1